Pfizer recalls blood pressure drug Accuretic due to potential carcinogen
Pfizer said it has not received any reports of adverse events related to the drug till date.
New Delhi: Pfizer Inc said on Monday it was recalling some lots of blood pressure drug Accuretic and two authorized cheaper versions of the drug due to the presence of elevated levels of a nitrosamine, a potential cancer-causing impurity.
Pfizer said it has not received any reports of adverse events related to the drug till date.
Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables. Exposure to the impurities above acceptable levels over long periods of time could increase the risk of cancer.
However, there is no immediate risk to patients taking the drug, Pfizer said.
Patients currently taking the products should consult with their doctor about alternative treatment options, the drugmaker said.
Pfizer Canada earlier this month recalled Accuretic due to the presence of the same impurity.
Last year, the drugmaker also recalled its anti-smoking treatment, Chantix, due to high levels of a nitrosamine in the pills.
Read Also - Pfizer, Bayer to maintain essential drug supply to Russia
Pfizer applies science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.
Read Also - PFIZER Clostridium difficile Vaccine did not meet primary endpoints: PHASE 3 CLOVER Trial
